Precision
Dutasteride
Designed to strongly inhibit scalp 5α-reductase while minimizing systemic absorption.
- 1Dutasteride inhibits both type I and type II isoenzymes for powerful suppression of scalp DHT.
- 2Anagen's proprietary delivery vehicle causes liposomes to preferentially aggregate in a follicular reservoir for localized diffusion to dermal papilla cells.
- 3Early before/after patient sampling shows no serum DHT reduction.
Why we deliver through the follicle.
Dutasteride is one of the most potent DHT blockers there is, but its target sits deep inside the follicle, and taken orally it suppresses DHT across the whole body. The entire job of a topical is to put that potency at the follicle and minimize systemic absorption. That's a delivery problem, and it's the one Precision Dutasteride's vehicle is built to solve.
- 1The target is deep and local. Inside the follicle, 5α-reductase converts testosterone into DHT, and DHT acts on the dermal papilla at the base of the follicle to miniaturize it. The drug has to reach the dermal papilla, locally, deep in the follicle.
- 2Flat skin blocks the way. The stratum corneum, the skin's outer "brick-and-mortar" layer (keratin cells packed in a lipid matrix), is the rate-limiting barrier to topical drugs; intact lipid vehicles essentially can't cross it.
- 3The follicle is the shortcut. The follicle opening bypasses that barrier: the drug and its lipid vesicles funnel down the follicular canal and pool in the sebum as a long-lived "follicular reservoir": reaching depth, and lingering, in a way flat-skin diffusion can't.
- 4A localized gradient does the targeting. Concentrating the drug in the follicle builds a steep local concentration gradient. By Fick's law, diffusion flows from high to low concentration: a strong push across the thin canal wall into the dermal papilla, exactly where it's needed. Because the depot is small and local, the outward gradient is weak, so little drug spreads to the deeper dermis or the bloodstream.
That is the whole rationale for follicular targeting: the local action of dutasteride with far less of the systemic trade-off. Which is why we screened dozens of vehicles for exactly this property, and the rest of this page is the evidence the vehicle actually does it.
More than 60 delivery systems went in. One came out ahead.
A vehicle is only as good as where it puts the drug. We screened the field (liposomes, ethosomes, transfersomes, polymer nanospheres and nanocapsules, mineral carriers) for one property: routing dutasteride into the follicle.
Early Precision Dutasteride patients show no decrease in serum DHT.
If the drug truly stays local, systemic DHT should barely move. Across six early patients we monitored serum DHT (ng/dL) at baseline and follow-up. This is real-world observational monitoring (n = 6), not a randomized or controlled endpoint.
Minimal systemic DHT change, consistent with a follicle-local topical that leaves circulating hormone largely unmoved.
In skin tests, the drug concentrates in the follicle with variability between wet and dry scalp.
Targeting only matters if the drug also stays put. Ex vivo, dutasteride accumulated in the follicle while the deeper viable-skin compartment (the path toward circulation) stayed below the assay's detection limit. More dutasteride was recovered from the follicle in wet scalp conditions compared to dry.
Dutasteride's hair-growth efficacy as a dual 5α-reductase inhibitor is well established and covered in depth elsewhere. This page is about delivery: getting that established molecule into the follicle while minimizing systemic absorption.
Targeted delivery
The winning vehicle routes drug into the follicle: 0.64 vs ≈ 0.47 for the best alternative.
Measured · ex vivoSerum DHT unmoved
Across 6 early patients, serum DHT showed no decrease (+10.6%); stays within range.
Observed · n = 6Stays local
Drug accumulates in the follicle; the systemic route stayed below detection.
Measured · ex vivoTwo strengths
Precision Dutasteride 0.03% and Maxx Precision Dutasteride 0.3%: clinician-dialed local dose.
ProductTwo strengths, one follicle-targeting vehicle.
A licensed clinician decides whether either is right for you.
What this page can and can't support
- Vehicle data is ex-vivo follicular targeting: a delivery measure (where the drug goes), not clinical hair growth, and not serum-DHT suppression on its own.
- The serum-DHT set is observational (n = 6), not a controlled PK or hormone study; stable DHT is the expected result for a topical, not proof of efficacy.
- Maxx Precision Dutasteride serum-DHT monitoring is pending: we report only what we've measured, and Maxx Precision Dutasteride hormone data is not yet available.
- Prescription product, clinician-gated. Suitability is decided by a licensed clinician. This page is treatment science, not medical advice.
